A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Eisai

Status: Completed

Conditions: Locally Advanced or Metastatic Breast Cancer

Treatments: Drug: Eribulin mesylate

Study type: Observational

Funder types: Industry

Identifiers

NCT03437083

E7389-M082-602

Details and patient eligibility

About

The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.

Enrollment: 340 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of locally advanced or metastatic breast cancer
• Participants who were treated with Eribulin between 01 June, 2014 and 31 December, 2016

Exclusion criteria

• Not applicable

Trial design

340 participants in 1 patient group

Eribulin

Description:

Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.

Treatment:

Drug: Eribulin mesylate